Cytosorbents Corporation ( NASDAQ: CTSO) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Peter J. Mariani - Chief Financial Officer Phillip P. Chan - CEO & Director Michael Anthony Sarcone ...

Early recognition and mitigation of drug and device integration difficulties are critical to the success of combination ...

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of ...

Explore the journey of Davide Marotta, a pioneer in space biomanufacturing at the International Space Station National Laboratory and beyond ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Q2 2025 Earnings Call Transcript August 6, 2025 LivaNova PLC beats earnings expectations. Reported EPS is $1.05, expectations were $0.84. Operator: Good day, ladies and gentlemen, and welcome to the ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ pipeline to focus more on complex generics—drugs that have complex ...

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter ...

FDA approval of IBTROZI (taletrectinib) transformed Nuvation Bio into a commercial-stage company, driving $4.8 million in GAAP revenue, well above GAAP revenue estimates. Earnings per share (GAAP) was ...